文献速递肝胆胰外科围术期管理与 ERAS

LigaSure与CUSA在肝硬化肝癌腹腔镜肝切除术中肝实质离断的倾向性评分匹配分析

LigaSure versus CUSA for parenchymal transection during laparoscopic hepatectomy in hepatocellular carcinoma patients with cirrhosis: a propensity score-matched analysis.
PubMed 文献 · Surg Endosc · 2017-11-09

该回顾性研究纳入135例肝硬化肝癌行纯腹腔镜肝切除术患者,按肝实质离断方式分为CUSA组55例与LigaSure组80例,经1:1倾向性评分匹配后每组48例。结果显示LigaSure组肝实质离断时间显著短于CUSA组,术中出血量、输血需求、术后再灌注损伤程度及并发症两组无显著差异,2年总生存率与无病生存率亦无显著差异,且LigaSure组总住院费用和术中费用显著更低。

要点

  • 肝硬化肝癌腹腔镜肝切除中LigaSure与CUSA均安全有效
  • LigaSure组肝实质离断时间显著短于CUSA组
  • LigaSure组住院总费用与术中费用显著低于CUSA组

核心结论

  • LigaSure与CUSA在肝硬化肝癌患者腹腔镜肝切除术中均安全有效。
  • LigaSure可能是一种简单、可行且成本效益好的手术技术,适用于经过选择的肝硬化肝癌患者。

研究设计与样本

  • 回顾性队列研究,纳入2015年1月至2017年5月四川大学华西医院135例背景肝硬化的肝细胞癌行纯腹腔镜肝切除术患者。
  • 按肝实质离断方式分为CUSA组55例与LigaSure组80例,行1:1倾向性评分匹配后每组48例。

主要发现

  • LigaSure组平均肝实质离断时间74.3±23.6 min,显著短于CUSA组的86.3±25.8 min(P=0.019)。
  • LigaSure与CUSA相比未增加术中出血量或输血需求。
  • 两组术后再灌注损伤程度及并发症无显著差异。
  • 两组2年总生存率与无病生存率无显著差异。
  • LigaSure组每例总住院费用(P=0.032)与术中费用(P=0.006)显著低于CUSA组。

临床怎么用

  • 在肝硬化肝癌患者行腹腔镜肝切除术时,可考虑使用LigaSure进行肝实质离断以缩短离断时间并降低费用。
  • 选择LigaSure需基于患者条件,该研究人群为经过选择的肝硬化肝癌患者。

局限性

  • 本研究为单中心回顾性研究。
  • 样本量有限,匹配后每组48例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: LigaSure has been reported as a safe and effective approach for parenchymal transection in open hepatectomy; however, its roles in laparoscopic hepatectomy (LH) with liver cirrhosis have not been evaluated. The aim of this study was to compare the outcomes of LigaSure vs. Cavitron Ultrasonic Surgical Aspirator (CUSA) for LH in hepatocellular carcinoma (HCC) patients with cirrhosis. METHODS: We retrospectively reviewed the medical records of 135 HCC patients with background cirrhosis who underwent pure LH using CUSA (n = 55) or LigaSure (n = 80) for parenchymal transection between January 2015 and May 2017 at West China Hospital of Sichuan University. We performed 1:1 propensity score matching between the LigaSure and CUSA groups. Subsequently, 48 patients were included in each group. RESULTS: The mean parenchymal transection time (74.3 ± 23.6 vs. 86.3 ± 25.8 min, P = 0.019) in the LigaSure group was obviously shorter than that in the CUSA group. The LigaSure did not increase the intraoperative blood loss or blood transfusion requirement when compared with CUSA. Moreover, the degree of postoperative reperfusion injury and complications were not significantly different between the two groups. Furthermore, there were no significant differences between the two groups regarding 2-year overall survival rate or disease-free survival rate. In addition, the total hospitalization costs (P = 0.032) and intraoperative costs (P = 0.006) per case were significantly lower in the LigaSure group than those in the CUSA group. CONCLUSION: The two devices were safe and effective for LH in patients with cirrhosis. The LigaSure method may be a simple, feasible, and cost-effective surgical technique for LH in selected HCC patients with cirrhosis.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Liu F, Wei Y, Li H, et al. LigaSure versus CUSA for parenchymal transection during laparoscopic hepatectomy in hepatocellular carcinoma patients with cirrhosis: a propensity score-matched analysis. Surg Endosc. 2017. PMID: 29124405. doi:10.1007/s00464-017-5947-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。